Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Gili Kenet,1,2 Thomas Moulton,3 Brian M Wicklund,4 Sanjay P Ahuja,5 Miguel Escobar,6 Johnny Mahlangu7 1National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel; 2The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel; 3Bayer, Whippany, NJ, USA; 4Children’...

Full description

Bibliographic Details
Main Authors:	Kenet G, Moulton T, Wicklund BM, Ahuja SP, Escobar M, Mahlangu J
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-06-01
Series:	Journal of Blood Medicine
Subjects:	fviii hemophilia a prophylaxis recombinant proteins octocog alfa
Online Access:	https://www.dovepress.com/switching-from-sucrose-formulated-rfviii-to-octocog-alfa-bay-81-8973-p-peer-reviewed-fulltext-article-JBM

Similar Items

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
by: Chia-Yau Chang, et al.
Published: (2023-03-01)

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
by: Raimondo De Cristofaro, et al.
Published: (2019-04-01)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01)

Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
by: Benson G, et al.
Published: (2021-01-01)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022-11-01)

Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1
by: Davide Matino, et al.
Published: (2020-04-01)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
by: Christian Lubich, et al.
Published: (2022-10-01)

In-Silico Characterization of von Willebrand Factor Bound to FVIII
by: Valentina Drago, et al.
Published: (2022-08-01)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
by: Nadia El-Akabawy, et al.
Published: (2020-06-01)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary P, et al.
Published: (2016-09-01)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
by: Carola Sella, et al.
Published: (2023-07-01)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
by: Teare JM, et al.
Published: (2019-03-01)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
by: Ritu M. Ramamurthy, et al.
Published: (2022-12-01)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
by: Carmen Escuriola Ettingshausen, et al.
Published: (2022-04-01)

Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A
by: Amanda M. Actor, et al.
Published: (2014-04-01)

Managing Relevant Clinical Conditions of Hemophilia A/B Patients
by: Massimo Morfini, et al.
Published: (2023-06-01)

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
by: Tischer B, et al.
Published: (2018-03-01)

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A
by: Rou Xiao, et al.
Published: (2024-03-01)

The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes
by: Valeria Porcheddu, et al.
Published: (2024-03-01)

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
by: Giancarlo Castaman, et al.
Published: (2023-03-01)

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
by: Paolo Angelo Cortesi, et al.
Published: (2022-06-01)

Intracranial Hemorrhage in Patients With Hemophilia A
by: Nugroho Setia Budi, et al.
Published: (2020-07-01)

Acquired Factor VIII Inhibitors: Three Cases
by: Tay Za Kyaw, et al.
Published: (2013-03-01)

Expert opinion paper on the treatment of hemophilia A with emicizumab
by: Francisco-José López-Jaime, et al.
Published: (2023-12-01)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
by: Zhenping Chen, et al.
Published: (2021-03-01)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
by: Kearney S, et al.
Published: (2019-04-01)

Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
by: Ole Jakob Jørgensen, et al.
Published: (2024-02-01)

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
by: Jamie O’Hara, et al.
Published: (2021-01-01)

Prophylaxis and hemophilia care in LATAM: Baring it all—Highlights from the CLAHT 2021 symposium
by: Giovanni G. DiMinno, et al.
Published: (2022-11-01)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
by: Ezio Zanon
Published: (2023-08-01)

A Novel Deletion Mutation of the F8 Gene for Hemophilia A
by: Jingwei Wang, et al.
Published: (2022-11-01)

Association of HLA class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A
by: Oytip Nathalang, et al.
Published: (2012-03-01)

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells
by: Yoshihiko Sakurai, et al.
Published: (2013-07-01)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
by: Marissa J.M. Traets, et al.
Published: (2020-10-01)

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A
by: Tomasz Urasiński, et al.
Published: (2023-02-01)